We are live on
!
Find out more
DA
DSC Advisors Portfolio holdings
AUM
$11M
1-Year Est. Return
5.88%
This Fund
S&P 500
This Quarter
Est. Return
-5.56%
1 Year Est. Return
+5.88%
3 Year Est. Return
+3.18%
5 Year Est. Return
+39.43%
10 Year Est. Return
+114.64%
AUM
$168M
AUM Growth
-$23.1M
(-12%)
Cap. Flow
-$95M
Cap. Flow
% of AUM
-56.41%
Top 10 Holdings %
Top 10 Hldgs %
59.36%
Holding
73
New
14
Increased
9
Reduced
26
Closed
17
Top Buys
| 1 |
Aptiv
APTV
|
+$5.13M |
| 2 |
Goldman Sachs
GS
|
+$3.86M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$1.89M |
| 4 |
JPMorgan Chase
JPM
|
+$1.64M |
| 5 |
Zevra Therapeutics
ZVRA
|
+$1.4M |
Top Sells
| 1 |
CVS Health
CVS
|
+$6.43M |
| 2 |
Cardinal Health
CAH
|
+$3.66M |
| 3 |
SWFT
Swift Transportation Company
SWFT
|
+$3.38M |
| 4 |
PRA Group
PRAA
|
+$3.29M |
| 5 |
NEOS
Neos Therapeutics, Inc
NEOS
|
+$2.58M |
Sector Composition
| 1 | Healthcare | 60.15% |
| 2 | Financials | 9.03% |
| 3 | Communication Services | 6.38% |
| 4 | Materials | 4.94% |
| 5 | Industrials | 4.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CVS Health
CVS
$136B
| $15.8M | 9.36% |
151,835
-66,096
| -30% | -$6.43M |
|
|
2
Cardinal Health
CAH
$53.6B
| $14.8M | 8.77% |
180,196
-45,009
| -20% | -$3.66M |
|
|
3
Zevra Therapeutics
ZVRA
$754M
| $13M | 7.7% |
55,847
+5,768
| +12% | +$1.4M |
|
|
FOMX
4
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $9.74M | 5.79% |
1,494,399
+85,802
| +6% | +$553K |
|
|
5
Goldman Sachs
GS
$323B
| $8.67M | 5.15% |
55,216
+24,934
| +82% | +$3.86M |
|
|
BERY
6
DELISTED
Berry Global Group, Inc.
BERY
| $8.31M | 4.94% |
250,470
-10,701
| -4% | -$312K |
|
7
HCA Healthcare
HCA
$85.6B
| $8.26M | 4.91% |
105,875
-357
| -0.3% | -$24.9K |
|
|
NEOS
8
DELISTED
Neos Therapeutics, Inc
NEOS
| $7.48M | 4.45% |
693,582
-245,016
| -26% | -$2.58M |
|
|
NSTG
9
DELISTED
NanoString Technologies, Inc.
NSTG
| $7.08M | 4.2% |
465,000
| – | – |
|
|
SWFT
10
DELISTED
Swift Transportation Company
SWFT
| $6.92M | 4.11% |
371,293
-208,707
| -36% | -$3.38M |
|
11
Elevance Health
ELV
$80.9B
| $6.27M | 3.73% |
45,129
+129
| +0.3% | +$17.2K |
|
|
12
Aptiv
APTV
$12.5B
| $5.63M | 3.34% |
+75,000
| New | +$5.13M |
|
|
PFNX
13
DELISTED
Pfenex Inc.
PFNX
| $4.92M | 2.92% |
500,000
+15,191
| +3% | +$133K |
|
|
PARA
14
DELISTED
Paramount Global Class B
PARA
| $4.68M | 2.78% |
85,000
| – | – |
|
|
15
PRA Group
PRAA
$702M
| $4.63M | 2.75% |
157,718
-114,282
| -42% | -$3.29M |
|
16
Biogen
BIIB
$30.8B
| $3.67M | 2.18% |
14,089
-22
| -0.2% | -$5.81K |
|
|
DVAX
17
DELISTED
Dynavax Technologies
DVAX
| $2.98M | 1.77% |
155,000
| – | – |
|
|
TWX
18
DELISTED
Time Warner Inc
TWX
| $2.75M | 1.63% |
37,922
-12,521
| -25% | -$862K |
|
19
Sunoco
SUN
$13.6B
| $2.48M | 1.48% |
75,000
| – | – |
|
20
Acadia Pharmaceuticals
ACAD
$4.39B
| $2.31M | 1.37% |
82,500
+17,500
| +27% | +$382K |
|
21
Amgen
AMGN
$201B
| $2.29M | 1.36% |
15,303
-74
| -0.5% | -$11K |
|
22
Microsoft
MSFT
$2.98T
| $2.02M | 1.2% |
36,655
-9,833
| -21% | -$515K |
|
|
23
Invesco QQQ Trust
QQQ
$466B
| $1.99M | 1.18% |
+18,183
| New | +$1.89M |
|
24
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
| $1.76M | 1.04% |
762,500
-537,500
| -41% | -$105M |
|
|
25
JPMorgan Chase
JPM
$912B
| $1.66M | 0.99% |
+28,078
| New | +$1.64M |
|
Similar funds
RJTCONH
HSC
BGC
ACM
AG
RVM
JDR
KM
DSC Advisors's Q1 2016 Portfolio in Review
As of Q1 2016, DSC Advisors held 73 positions worth $168M, down 12% from $191M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
DSC Advisors withdrew a net $95M in Q1 2016, closing 17 positions and reducing 26 holdings. Its most notable exit was Accelerate Diagnostics, an estimated $2.45M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 66% a quarter earlier, followed by Financials and Communication Services.
Against the trend, DSC Advisors opened a new position in Aptiv worth $5.63M.
- DSC Advisors's largest Q1 2016 buy was Aptiv: 75,000 shares worth $5.63M.
- DSC Advisors added most to Goldman Sachs in Q1 2016, an estimated $3.86M increase.
- DSC Advisors's biggest Q1 2016 reduction was CVS Health, cutting an estimated $6.43M.
- DSC Advisors fully exited Accelerate Diagnostics in Q1 2016, selling an estimated $2.45M.
- DSC Advisors's ten largest holdings make up 59% of its $168M portfolio in Q1 2016.
- DSC Advisors opened 14 new positions and closed 17 in Q1 2016.
- DSC Advisors's portfolio value fell 12% quarter-over-quarter to $168M.
Based on DSC Advisors's 13F filing for Q1 2016, filed 16 May 2016.